| Trial ID: | L1183 |
| Source ID: | NCT03499639
|
| Associated Drug: |
Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet
|
| Title: |
Ombitasvir/ Paritaprevir / Ritonavir Plus Ribavirin in Management HCV and End-stage Kidney Disease
|
| Acronym: |
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
End-stage Renal Disease|HCV Coinfection
|
| Interventions: |
DRUG: Ombitasvir / Paritaprevir / Ritonavir /Ribavirin Oral Tablet
|
| Outcome Measures: |
Primary: The primary endpoint was the achievement of SVR at week 12 (SVR12) post-treatment., 6 months | Secondary: The potential adverse events were evaluated in each visit for the development of adverse events or any significant interactions., 6 months
|
| Sponsor/Collaborators: |
Sponsor: Assiut University | Collaborators: Sohag University|South Valley University
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
110
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NA|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2018-05-01
|
| Completion Date: |
2018-09-30
|
| Results First Posted: |
|
| Last Update Posted: |
2020-01-10
|
| Locations: |
Assiut University Hopsital, Assiut, 71515, Egypt
|
| URL: |
https://clinicaltrials.gov/show/NCT03499639
|
